Potential Covid-19 drug developed by Singapore-based firm to start final trial in a few weeks

  • 📰 The Straits Times
  • ⏱ Reading Time:
  • 42 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 20%
  • Publisher: 63%

Singapore Headlines News

Singapore Latest News,Singapore Headlines

The monoclonal antibody - or immune system protein known as TY027 - will be tested on 500 recently diagnosed Covid-19 patients.. Read more at straitstimes.com.

SINGAPORE - Trials for a potential treatment of Covid-19 are being accelerated, with the third and final phase for the drug due to start in a few weeks' time.

Professor Ooi Eng Eong of Duke-NUS Medical School, who is one of the founders of Tychan, told The Straits Times on Thursday that as a small company, Tychan does not have the resources to run trials with thousands of patients. Monoclonal antibodies are immune system proteins that are created in the laboratory, and can be specially designed and engineered to target Sars-CoV-2, the virus that causes Covid-19.

The process of recruitment has not started yet, because the final trial is pending approval from the authorities - the Health Sciences Authority and an ethics board. As for how long the trial will take, this would depend on how fast the 500 patients can be recruited. Usually in phase three, what is being tested is whether the drug works as intended, such as preventing disease or accelerating recovery.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 8. in SG

Singapore Latest News, Singapore Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

AstraZeneca in deal with Kangtai Bio to supply potential COVID-19 vaccine in ChinaAstraZeneca PLC has signed an exclusive framework agreement with China's Shenzhen Kangtai Biological Products to supply its COVID-19 vaccine ...
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »

COVID-19: Singapore confirms 908 new cases as final batch from dormitories being clearedThe Ministry of Health has confirmed 908 new COVID-19 cases as of Wednesday (5 August) noon, bringing Singapore’s total to 54,254.
Source: YahooSG - 🏆 3. / 71 Read more »

908 new Covid-19 cases in Singapore, including 4 in community[SINGAPORE] There were 908 new coronavirus cases confirmed as of Wednesday noon, taking Singapore's total to 54,254. Read more at The Business Times.
Source: BusinessTimes - 🏆 15. / 51 Read more »

301 new Covid-19 cases in Singapore, including 4 in the community and 4 imported[SINGAPORE] There were 301 new coronavirus cases confirmed as at Thursday noon, taking Singapore's total to 54,555. Read more at The Business Times.
Source: BusinessTimes - 🏆 15. / 51 Read more »

Singapore will get first claim to any successful Arcturus Covid-19 vaccine[SINGAPORE] Singapore sought out US Covid-19 vaccine developer Arcturus Therapeutics Holdings and is funding its research in order to secure the first doses of any successful final product, in a reflection of the growing urgency in the race for immunisation. Read more at The Business Times.
Source: BusinessTimes - 🏆 15. / 51 Read more »

COVID-19: Singapore confirms 301 new cases, four in the communityThe Ministry of Health has confirmed 301 new COVID-19 cases as of Thursday (6 August) noon, bringing Singapore’s total to 54,555.
Source: YahooSG - 🏆 3. / 71 Read more »